(Q41016205)

25 September 2017

title

Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy (English)

1 reference

25 September 2017

1 reference

1 reference

1 reference

1 reference

6

David Y Graham

1 reference

25 September 2017

Wei Zhang

1

1 reference

25 September 2017

Qi Chen

2

1 reference

25 September 2017

Xiao Liang

3

1 reference

25 September 2017

Wenzhong Liu

4

1 reference

25 September 2017

Shudong Xiao

5

1 reference

25 September 2017

Hong Lu

7

1 reference

25 September 2017

language of work or name

English

0 references

publication date

2 September 2015

1 reference

25 September 2017

1 reference

25 September 2017

volume

64

1 reference

25 September 2017

issue

11

1 reference

25 September 2017

page(s)

1715-1720

1 reference

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Helicobacter pylori treatment in the era of increasing antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Helicobacter pylori and antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

H pylori antibiotic resistance: prevalence, importance, and advances in testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

Management of Helicobacter pylori eradication--the influence of structured counselling and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309900

10.1136/GUTJNL-2015-309900

21 January 2018

Identifiers

DOI

1 reference

25 September 2017

1 reference